| Sue Ellen Howard, RN, MSN-I | |
|
1685 Marietta Rd, Chillicothe, OH 45601-9465 | |
| (740) 649-6870 | |
| Not Available |
| Full Name | Sue Ellen Howard |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 1685 Marietta Rd, Chillicothe, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043935885 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | RN.217036 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sue Ellen Howard, RN, MSN-I 1685 Marietta Rd, Chillicothe, OH 45601-9465 Ph: (740) 649-6870 | Sue Ellen Howard, RN, MSN-I 1685 Marietta Rd, Chillicothe, OH 45601-9465 Ph: (740) 649-6870 |
News Archive
A drug that has been used for 40 years for the treatment of skin fungus has been found to be a possible cancer treatment, according to an international team of scientists. Leslie Wilson, professor of biochemistry and pharmacology at the University of California, Santa Barbara, said that the antifungal drug, griseofulvin, has been shown to inhibit the growth of cancer cells in his laboratory.
Stress. Work. Kids. Managing a household. These are just a few of life's daily obstacles that keep people from getting enough sleep. On top of the tasks that prevent you from going to bed are the worries that keep you up once you get there, such as relationship issues, family illness or financial stress.
A new study by Canadian researchers may pave the way for more effective treatment of an aggressive and deadly type of brain tumour, known as ETMR/ETANTR. The tumour, which is seen only in children under four, is almost always fatal, despite aggressive treatment. The study proposes a new model for how this brain tumour develops and suggests possible targets to investigate for novel therapies.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 1 days ago
Mr. Christopher James Bonine, APRN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 17273 State Route 104, Chillicothe, OH 45601 Phone: 740-773-1141 | |
Ashely Nicole Trefz, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 17273 Oh-104, Chillicothe, OH 45601 Phone: 740-773-1141 | |
Mrs. Bryla Layne Elder, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 17273 State Route 104, Chillicothe, OH 45601 Phone: 740-773-1141 | |
Ronald Eugene Pettit, CNS Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 17273 State Route 104, Chillicothe, OH 45601 Phone: 740-773-1141 | |
Ms. Angela Rani Ruggles, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1503 Stone Road, Chillicothe, OH 45601 Phone: 740-253-7313 | |
Marilyn Alexandra Cherrington, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 17273 State Route 104, Chillicothe, OH 45601 Phone: 740-418-8305 | |
Courtney Dawn Durham, CNP Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 272 Hospital Rd, Chillicothe, OH 45601 Phone: 740-779-7500 |